Oops! Something went wrong while submitting the form.
Oxford Cancer Analytics is transforming curative cancer treatments through a minimally invasive blood test and machine learning.
We are on a mission to save lives and drastically improve cancer management through early detection, with machine learning and an affordable blood testJoin our team
Oxford Cancer Analytics focuses on strategic beachhead markets in lung cancer for expedited product deployment.
Applying state-of-the-art machine learning for multidimensional liquid biopsy data with a focus on protein enables maximised detection accuracy compared to leading competitors.
OXcan has international partnerships focussing on all aspects of lung cancer management, from high risk screening, to early recurrence detection and personalised treatment stratification.
Peter Liu has a decade of experience in cancer and molecular biology research and health innovation translation. He has clinical medicine training from the University of Toronto and completed a DPhil in Clinical Medicine at the University of Oxford where he was the recognized as an Oxford-Hoffman International Scholar and Jesus College Graduate Scholar for academic merit. He was President of the Oxford University Scientific Society, oldest society of its kind in the world, and the Executive Director of BRIGHT International, a health innovation think tank focusing on strategic implementation of medical innovations. His cancer research and medical innovation experiences span four continents, including having worked at the World Health Organisation.
Chief Executive Officer
Andreas Halner has a unique combination of medical and mathematical training. Andreas completed pre-clinical medicine and a DPhil in Clinical Medicine and Machine Learning at the University of Oxford. Andreas is a St Johns’ College, University of Oxford Casberd Scholar for academic excellence. He holds the Pathology Tutor for Medicine post at St John’s College. Andreas is also the Chief Data Scientist of a European Clinical Research Collaboration on lung disease and has designed statistical analysis plans for a European-wide clinical trial. He has designed multiple new mathematical and clinical paradigms for defining disease states, developing algorithms for treatment outcome prediction and treatment monitoring.
President & Chief Operating Officer
Junetha Syed Jabarulla graduated from Madurai Kamaraj University (India) in Microbial gene Technology. Following her Master’s she worked at the Department of Biotechnology, IIT Madras focusing on the Functional characterization of RASSFs in Lung adenocarcinoma through whole transcriptomics analysis. She received the Mitsubishi Corporation International Scholarship during her PhD in Chemical Biology at Kyoto University, Japan. Her PhD thesis focused on developing programmable DNA-binding small molecules as a therapeutic strategy to target the oncogene EVI1 at the transcription level. Following her PhD, Junetha joined as a Post-Doctoral researcher in the Department of Oncology, University of Oxford where she was working with DNA Repair in Cancer Treatment and Chromosome integrity groups on the identification of HDAC inhibitor targets in DNA repair pathway to lead new drug combinations or biomarker to increase the efficiency of radiotherapy and targeting H3K36me3-deficient cancer cells with new class of WEE1 inhibitor respectively. With more than a decade experience in target and biomarker discovery in cancer research Junetha has joined OXcan as a chief scientist.
Chief Scientific Officer
Daniel Szulc is a physiologist turned engineer with a passion for innovation, collaboration, and communication. After completing a double major in physiology and chemistry he went on to achieve a doctorate in biomedical engineering at the University of Toronto, where he was recognized as a UofT Top Scholar and Graduate to Watch for his impact as a STEM innovator and role model. His academic and industrial research spans the fields of biology, chemistry, medicine and physics and has led to several peer-reviewed manuscripts, inventions and collaborative projects awarded millions of research funding geared towards clinical translation. Alongside his passion for research and discovery, Daniel has actively sought to promote scientific communication and translation by leading the operations and strategic initiatives of both a national not-for-profit, Science Rendezvous, and an early-stage medtech start-up, Integral Health Systems, which developed next-generation software tools for surgical staff and medical personnel. Through these endeavours, he established national initiatives which engaged 25,000 students and created interdisciplinary networks with over 1600 scientists, clinicians, and engineers from 100 different academic disciplines across North America.
Chief Product Officer
Iliyana has over a decade of experience in proteomics and mass spectrometry. She graduated from the University of Sheffield with a Masters of Science degree with honours in Medical Genetics and a PhD in Molecular Biology. In the early years of her scientific career, she worked on anti-cancer drug resistance, genetic mutations of Von Willebrand disease and novel centromeric chromatin components. During her PhD, Iliyana combined her interest in Genetics and Proteomics when she engineered genetic mutants of yeast in order to study protein interactions by mass spectrometry and microscopy techniques. In 2016, she did an internship at Oxford University Innovation where she increased her awareness of technology transfer and intellectual properties. After that, Iliyana continued to do research in the Proteomics field for several years before joining OXcan in 2023. Most recently, she worked on Covid-19 biomarker discovery at the University of Liverpool. Iliyana is a member of the British Mass Spectrometry Society and the British Society for Proteomes Research.
Harini is a keen scientist and biotechnologist with over 7 years of international training experience in cancer research. She received her first graduate level MSc degree in Infection biology from Uppsala University, Sweden and focussed on working with oncolytic viral vectors as effective novel approaches for targeted cancer treatment. She then pursued a second MSc degree in Biomedical Technology from Robert Gordon University, Scotland.
As an immunoassay scientist passionate about working with molecular biology techniques, she is dedicated to advancing cancer early detection through her collaborative work with the OXcan team.
Safia is a Senior Machine Learning Scientist with over 10 years of experience in machine learning and deep scientific understanding of medical data, driven by a genuine passion for improving healthcare and patient outcomes.
Her achievements include the development of Class-1 medical devices used in NHS hospitals, extensive analyses of anonymised medical data to discover novel medical insights, the creation of new and effective approaches to diagnosing complex diseases at early stages and providing personalised treatment pathways for patients.
She completed a PhD in Computer Science at the University of Sao Paulo in Brazil and worked as a post-doctoral fellow to identify how healthcare can benefit from the application of machine learning models for complex and high-dimensional medical data.
She has since worked as a Machine Learning Researcher in digital healthcare solutions bringing vital skills and valuable efforts in digitising healthcare.
Safia also holds masters and engineering degrees in Computer Science from the University of Bejaia, Algeria.
Senior Machine Learning Scientist
Luke Hankey graduated from the University of Liverpool in 2019 with a degree in Biological and Medical Sciences with a project focus on lysis of cancer cells. Throughout his studies, he acquired the Liverpool Excellence Scholarship as merit for his work. He has since developed applications to showcase his passion for coding and combined this with his strong academic background. He has now moved into the field of Machine Learning as a Junior Programmer to aid in the statistical analysis of biological and clinical datasets.
Machine Learning Programmer
Ella Mi is a medical doctor specializing in oncology with a dual background in computer science. She holds an NIHR Academic Clinical Fellowship in medical oncology at Oxford, and has led preclinical and clinical cancer research studies at the University of Cambridge and Imperial College London, with notable research achievements that includes identifying the most common genetic alteration in splenic marginal zone lymphoma, leading a longitudinal gastric cancer screening study and a machine learning programme to improve prognostication of brain tumours, which won the prestigious National Cancer Research Institute Award and received media coverage internationally. She obtained a 1st class Bachelor’s degree in Biochemistry and a medical degree at the University of Cambridge and has undertaken her Masters in Computer Science at the University of Oxford as a DeepMind Scholar. Ella has a keen interest in accelerating the clinical uptake of new medical technologies, and previously worked on Interventional Procedures at NICE and on commercial projects with Google Health and Huma.
Head of Medical and Regulatory Affairs
Zhu is a proteomic scientist, who is passionate about biotechnology and medicine. He received his first PhD in Biochemistry & Molecular Biology in Peking Union Medical College, Tsinghua University (Wu Hsien Prize, 2018), where he focused on the investigation of non-coding RNA in pulmonary diseases using next-generation sequencing, and quantitative analysis of ribonucleoside modifications in RNA using UPLC-MS/MS. He is currently finishing his second D.Phil in Clinical Medicine (CAMS-Oxford Innovative Talent Studentship) in TDI Mass Spectrometry Laboratory, University of Oxford, where he focused on spatiotemporally mapping protein-protein interaction networks using mass spectrometry-based proteomic approaches (APEX2 proximity labelling-MS, affinity purification-MS, and LOPIT). With more than eight years of experience in multi-omic approaches (transcriptomics, proteomics and interactomics), Zhu joined OXcan as a proteomic scientist.
Brad Wilson is former President Europe for GlaxoSmithKline (GSK) with two decades of leadership experience. Mr Wilson led sales in excess of £1.5bil and sales growth of 15%, across the 5000-person pan-European organisation. His focus on marketing and new product introduction accounted for 25% of total sales. An experienced board member with a strong record of accomplishment in pharmaceutical and healthcare areas, he has founded and invested in a number of successful start-up companies including being CEO of the e-Health company OnMedica and the 24/7 Live-in Care business EnViva Ccare Ltd. Brad Wilson has been a critical mentor for OXcan, supporting strategy, fundraising, external support, and scaling up.
Marcus is a digital technology and product leader with a passion for driving positive change through the use of technology — a love affair that started when he was taught to program in elementary school at the age of nine.
Since then, he has built a reputation for being a 'creative technologist,’ someone who enjoys solving difficult problems in innovative ways, whether they are complex business challenges or life-changing social issues. He has spent one half of his career working for top technology companies building world-class technology (Apple, Google & IBM) and the other half helping brands to harness the power of technology to drive business value — including Comic Relief, Marks and Spencer, and National Geographic.
Today he is SVP & Chief Digital Officer at T-Mobile USA, America’s supercharged "Un-carrier" delivering an advanced 4G LTE and transformative nationwide 5G network that offers reliable connectivity for all. Marcus attended The Latymer Grammar School in London and subsequently read for an honors degree at the London Metropolitan University majoring in Management & Information Technology, and a Master’s in Management (major in Social Enterprise) from the University of Cambridge.
He is a Fellow of the BCS (British Computer Society) Chartered Institute for Information Technology (FBCS) and a Member of the Chartered Management Institute (MCMI). He is an Expert in Residence for the University of Oxford Foundry.Before moving to the United States he was an elected councillor for the London Borough of Enfield, representing Chase Ward. Today, he lives in San Francisco with his wife and their cat, Cesaré and puppy, Bella. In his spare time, he enjoys watching soccer, building computers, investigating tech for social good, artificial intelligence and traveling to unusual and exotic places around the world.
Dr. Cheng-Zhi Wang graduated from Peking University Health Science Center. He subsequently conducted tumor targeted therapy and gene regulation research at the Cancer Research Center, Missouri University (USA), the National Institute of Biological Sciences (NIBS) and the Institute of Biophysics of the Chinese Academy of Sciences. Upon transition to industry, Dr. Wang has successively engaged in drug R&D and clinical trials in well-known innovative drug CROs and pharmaceutical companies. He is currently the Chief Scientist and Vice President of the Life Science Business Unit at Megarobo.
Professor Benedikt Kessler is Professor of Biochemistry and Mass Spectrometry at the Target Discovery Institute, University of Oxford. His research has focused on proteomics, ubiquitin and protease biology. Some of his work has dealt with defining the molecular signatures in human disease processes and accelerating target discovery in translational research, such as cancer detection and treatment. He has published over 290 manuscripts in top peer-reviewed journals including Nature, Science, and Cell. Professor Kessler is a member of the British Mass Spectrometry Society, the British Society of Cell Biology and the American Association for Cancer Research.
Learn more about our collaborationsFind out more
Science & Healthcare
Ones to watch for 2021
1 in 10 annually
1 in 8 annually
BioEscalator, Innovation Building
Old Road Campus, Roosevelt Drive
100 College St, Suite 150,
BioEscalator, Innovation Building
Roosevelt Drive, Oxford,
Banting Institute, 100 College St, Suite 150,
© Oxford Cancer Analytics 2021
Find us on